Establishment Labs (NASDAQ:ESTA) Price Target Raised to $86.00

Establishment Labs (NASDAQ:ESTA) had its target price boosted by stock analysts at Needham & Company LLC from $84.00 to $86.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 11.90% from the stock’s current price.

ESTA has been the subject of a number of other reports. BTIG Research lifted their price target on Establishment Labs from $81.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Canaccord Genuity Group raised their price objective on Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. upped their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Finally, Citigroup boosted their price objective on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus price target of $79.14.

Establishment Labs Stock Up 2.5%

NASDAQ ESTA traded up $1.89 during trading on Tuesday, hitting $76.85. 676,329 shares of the company traded hands, compared to its average volume of 498,245. The business has a fifty day simple moving average of $70.88 and a 200 day simple moving average of $57.41. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $78.25. The company has a market capitalization of $2.23 billion, a P/E ratio of -26.88 and a beta of 0.99.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The firm had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. During the same quarter last year, the firm posted ($1.19) EPS. The company’s revenue was up 45.2% on a year-over-year basis. As a group, sell-side analysts predict that Establishment Labs will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP purchased a new position in shares of Establishment Labs during the 3rd quarter valued at $34,000. Kestra Advisory Services LLC bought a new stake in Establishment Labs during the fourth quarter valued at approximately $47,000. State of Wyoming bought a new position in Establishment Labs in the third quarter valued at $71,000. Osaic Holdings Inc. increased its position in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. Finally, CWM LLC raised its stake in shares of Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after acquiring an additional 686 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs News Roundup

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 headline beat — ESTA reported EPS of ($0.09) vs. consensus ($0.22) and revenue of $64.62M vs. $63.8M, with revenue up ~45% year‑over‑year; the beat and sharp narrowing of losses are the main near‑term bullish drivers. Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: FY‑2026 revenue guidance slightly above consensus — management guided revenue to $264.0M–$266.0M (vs. consensus ~$263.2M), signaling continued top‑line momentum that supports valuation, especially given strong recent growth. Press Release / Guidance
• Neutral Sentiment: Investor materials available — the full Q4 earnings call transcript and the conference call recording give more detail on margin progression, international demand and R&D cadence; useful for gauging whether beats are durable. Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst/industry coverage and previews point to earnings improvement but still highlight execution risk; comparison pieces and previews can help investors benchmark ESTA versus peers. Comparing Establishment Labs (NASDAQ:ESTA) and Pediatrix Medical Group (NYSE:MD) Establishment Labs earnings up next as losses narrow sharply
• Negative Sentiment: Still unprofitable with wide negative margins — Q4 showed a negative net margin (~43.5%) and return on equity is deeply negative; consensus still expects multi‑year losses (street EPS forecast for the current fiscal year remains negative), which caps valuation upside until sustained profitability. MarketBeat Q4 results summary
• Negative Sentiment: Balance‑sheet/leverage considerations — reported debt‑to‑equity and other leverage metrics are elevated, which increases sensitivity to slower growth or margin pressure and could limit investor appetite until cash flow turns positive. MarketBeat Financials

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.